CD4 and Thrombocytopenia: The results showed that no publication bias was found for ORR, QOL, myelosuppression, thrombocytopenia, anemia, gastrointestinal toxicity, liver toxicity, renal toxicity, or CD4+/CD8+ T cell ratios (p = 0.32, 95% CI −0.81–2.41; p = 0.68, 95% CI −1.20–1.81; p = 0.15, 95% CI −3.84–0.62; p = 0.34, 95% CI −1.84–0.64; p = 0.49, 95% CI −2.64–1.36; p = 0.73, 95% CI −0.96–1.37; p = 0.44, 95% CI −0.72–1.60; p = 0.52, 95% CI −1.43–0.75; and p = 0.11, 95% CI −1.43–12.04, and the trials objectively reported them.